News

Breakthrough Patent for Ibogaine Therapy by Clearmind Medicine

Breakthrough Patent for Ibogaine Therapy by Clearmind Medicine

Clearmind Medicine Inc. Makes Significant Move with New Patent

Clearmind Medicine Inc. (NASDAQ: CMND) has recently taken a big step by submitting an international patent application for an innovative combination therapy that aims to transform mental health treatment. This groundbreaking approach mixes Ibogaine with N-Acylethanolamines, enhancing the safety and effectiveness of therapies designed to tackle substance use disorders.

Partnership with SciSparc Ltd.

This state-of-the-art therapy stems from a partnership between Clearmind Medicine and SciSparc Ltd. (NASDAQ: SPRC). Together, they've created a distinctive blend of the psychedelic compound Ibogaine and Palmitoylethanolamide (PEA), which is part of the N-Acylethanolamines family. Their shared aim is to boost the therapeutic effects of Ibogaine while reducing the associated risks.

The Benefits of Ibogaine

Ibogaine, derived from the roots of the African shrub Tabernanthe iboga, has displayed significant potential in combating various addiction issues, including dependencies on opioids and cocaine. However, its use has been controversial due to reports of adverse effects that can arise from its consumption. Therefore, developing a safer combination therapy could herald a new beginning for those grappling with addiction.

Significance of the Patent

This recent patent application represents an important step forward in treatments for both mental health issues and substance use disorders. By securing this patent, Clearmind Medicine underscores its dedication to innovation and its role as a leader in the psychedelic therapy arena. As CEO Adi Zuloff-Shani remarked, “The publication of this patent highlights our commitment to finding effective and safe solutions for mental health challenges that remain poorly addressed in modern healthcare.”

Prioritizing Safety

With the goal of reducing the risks of side effects and fatalities often linked to Ibogaine treatments, Clearmind Medicine is at the forefront of ensuring patients can access options that are not only effective but also significantly safer for their mental health needs.

Focus on Innovation and Research

SciSparc is also well-known for its groundbreaking efforts in developing treatments for central nervous system disorders. The collaboration between SciSparc and Clearmind aims to advance psychedelic research, seeking broadened applications in various mental health conditions. With expertise in clinical-stage therapeutics, SciSparc provides essential knowledge that complements Clearmind’s emphasis on psychedelic-assisted therapies.

Strong Intellectual Property Portfolio

Currently, Clearmind Medicine boasts a solid intellectual property portfolio, which includes 19 patent families and 29 granted patents. This extensive collection highlights the company's commitment to pioneering innovative treatments and strengthening its position in the industry.

Looking to the Future

In conclusion, Clearmind Medicine's innovative patent is a significant advancement for mental health treatments, especially in the field of addiction recovery. With ongoing research and development initiatives, the partnership between Clearmind and SciSparc could lead to safer and more effective therapeutic options for those facing mental health challenges.

Frequently Asked Questions

What is the focus of Clearmind Medicine's new patent?

The new patent focuses on a combination therapy that involves Ibogaine and N-Acylethanolamines, aiming to improve treatment efficacy and safety.

How does Ibogaine help in treating addiction?

Ibogaine has shown potential in addressing substance use disorders, particularly opioid and cocaine dependencies, by facilitating withdrawal and reducing cravings.

Who is collaborating with Clearmind Medicine?

Clearmind Medicine is collaborating with SciSparc Ltd. to advance the development of this combination therapy.

What are the risks associated with Ibogaine?

Although Ibogaine shows therapeutic promise, there have been reports of adverse effects, including fatalities, prompting the need for safer treatment combinations.

How many patents does Clearmind Medicine hold?

Clearmind Medicine currently holds a portfolio of 19 patent families and has been granted 29 patents to date.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

China Southern Airlines Marks 70th Anniversary in NYC

Updated Category News Views 4

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 3

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
Endurance Energy's Modular Tech Revs Up Southeast Asia

Updated Category News Views 4

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 5

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Timur Turlov Leads FIDE with Chess and Digital Focus

Updated Category News Views 5

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Continue Reading
AI and Storytelling Make Waves in Science Education

Updated Category News Views 5

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
Farm Aid 2026: A Resilient Tribute to Family Farmers

Updated Category News Views 5

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 5

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
AST SpaceMobile Faces Class Action Over Misstatements

Updated Category News Views 4

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Continue Reading

Top 5 Most Recently Viewed Articles

Find Comfort and Assurance This Fall at Gate of Heaven

Updated Category News Views 97

Experience Comfort and Connection This Fall at Gate of Heaven This autumn, as the leaves turn and a spirit of reflection emerges, families are warmly invited to the Gate of Heaven Cemetery and Mausoleum for a special Fall Open House weekend. This event aims to foster connections among families while providing valuable insights into the significance of memorial planning....

Continue Reading
Lauren Cody to Lead Orangetheory Fitness as Brand President

Updated Category News Views 491

Lauren Cody Takes the Helm at Orangetheory Fitness Purpose Brands, LLC has exciting news! The organization, known for its significant contributions to the fitness, health, and wellness sector, is proudly announcing the appointment of Lauren Cody as the brand president of Orangetheory Fitness. With over twenty-five years of rich experience in leading substantial franchise...

Continue Reading
BofA Downgrades Nissan: Competition Fears and Sales Outlook

Updated Category News Views 126

BofA Downgrades Nissan Shares Due to Rising Competition BofA Securities has decided to downgrade Nissan Motor Co Ltd (OTC: NSANY), changing its stock rating from Buy to Underperform. This notable shift points to worries over various obstacles that might hinder the automaker's performance in the future. Revised Price Target Indicates Ongoing Challenges The investment firm...

Continue Reading
Momcozy Celebrates Community Spirit with Charity Contest Success

Updated Category News Views 206

Momcozy Celebrates the Winners of the Charity Contest Momcozy, a leading global mother and baby brand, is excited to share the results of its 'Love in Action' Charity Contest. This initiative was part of a larger campaign aimed at promoting comfort, health, and well-being for mothers everywhere. In total, $30,000 was awarded to three remarkable organizations that are...

Continue Reading
FDA Approves SELARSDI™: A New Era in Biologics

Updated Category News Views 647

Exciting News: SELARSDI™ Receives FDA Approval Teva Pharmaceuticals, in collaboration with Alvotech, has made significant strides in the field of biosimilars. Recently, the U.S. Food and Drug Administration (FDA) granted approval for SELARSDI™ (ustekinumab-aekn), marking it as interchangeable with the established biologic, Stelara® (ustekinumab). This...

Continue Reading